Pharma company Roche and stem cell experts Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies gain access to key disease modeling patents from Ncardia.
The financial terms of the agreements were not disclosed.
Ncardia was recently formed through the merger of Axiogenesis and Pluriomics.
“The two companies have pioneered the development of stem cell derived cells for drug discovery and safety and in particular have advanced disease and tissue modeling applications,” said Ncardia.
“The Ncardia patent portfolio consists of several granted patents in Europe, the USA and Japan.
“The drug screening and disease modeling technology not only involves patient iPSC cells, induction of the disease phenotype can also be achieved through genetic manipulation, mRNA or siRNA transfection or through chemical or physical induction.”
Ncardia CEO Stefan Braam said: “Ncardia mission is to support and enable our clients to make better medicines faster.
“The combination of iPSC derived disease models with phenotypic screening is an extremely powerful method to identify new drug candidates.
“This license marks a further step in Ncardia technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and development market.”